A multi-dose vial from Amgen
KANJINTI(TM) IS AVAILABLE IN A
420 MG MULTI-DOSE VIAL(1)
image
image
image
  Learn more at KANJINTI.com  
Multi‑use when reconstituted with Bacteriostatic Water for Injection.
image
 
IMPORTANT SAFETY INFORMATION AND INDICATIONS
Boxed WARNINGS and Additional Important Safety Information
Cardiomyopathy
Trastuzumab products administration can result in sub‑clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline‑containing chemotherapy regimens
Evaluate left ventricular function in all patients prior to and during treatment with KANJINTI™. Discontinue KANJINTI™ treatment in patients receiving adjuvant therapy and withhold KANJINTI™ in patients with metastatic disease for clinically significant decrease in left ventricular function
Infusion Reactions; Pulmonary Toxicity
Trastuzumab products administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt KANJINTI™ infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue KANJINTI™ for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome
Embryo‑Fetal Toxicity
Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception
Cardiomyopathy
Administration of trastuzumab products can result in sub‑clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline‑containing chemotherapy regimens. In a pivotal adjuvant breast cancer trial, one patient who developed CHF died of cardiomyopathy
Trastuzumab products can cause left ventricular cardiac dysfunction, arrhythmias, hypertension, disabling cardiac failure, cardiomyopathy, and cardiac death
Trastuzumab products can also cause asymptomatic decline in left ventricular ejection fraction (LVEF)
Discontinue KANJINTI™ treatment in patients receiving adjuvant breast cancer therapy and withhold KANJINTI™ in patients with metastatic disease for clinically significant decrease in left ventricular function
Cardiac Monitoring
Evaluate cardiac function prior to and during treatment. For adjuvant breast cancer therapy, also evaluate cardiac function after completion of KANJINTI™
Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan
Monitor frequently for decreased left ventricular function during and after KANJINTI™ treatment
Monitor more frequently if KANJINTI™ is withheld for significant left ventricular cardiac dysfunction
Infusion Reactions
KANJINTI™ administration can result in serious and fatal infusion reactions
Symptoms usually occur during or within 24 hours of KANJINTI™ administration
Interrupt KANJINTI™ infusion for dyspnea or clinically significant hypotension
Monitor patients until symptoms completely resolve
Discontinue KANJINTI™ for infusion reactions manifesting as anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome. Strongly consider permanent discontinuation in all patients with severe infusion reactions
Infusion reactions consist of a symptom complex characterized by fever and chills, and on occasion include nausea, vomiting, pain (in some cases at tumor sites), headache, dizziness, dyspnea, hypotension, rash, and asthenia
Embryo‑Fetal Toxicity
Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception
Verify the pregnancy status of females of reproductive potential prior to the initiation of KANJINTI™
Advise pregnant women and females of reproductive potential that exposure to KANJINTI™ during pregnancy or within 7 months prior to conception can result in fetal harm
Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of KANJINTI™. Advise female patients to contact their healthcare provider with a known or suspected pregnancy
Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for KANJINTI™ treatment and any potential adverse effects on the breastfed child from KANJINTI™ or from the underlying maternal condition
Pulmonary Toxicity
Trastuzumab products can result in serious and fatal pulmonary toxicity, which includes dyspnea, interstitial pneumonitis, pulmonary infiltrates, pleural effusions, noncardiogenic pulmonary edema, pulmonary insufficiency and hypoxia, acute respiratory distress syndrome, and pulmonary fibrosis. Such events can occur as sequelae of infusion reactions
Patients with symptomatic intrinsic lung disease or with extensive tumor involvement of the lungs, resulting in dyspnea at rest, appear to have more severe toxicity
Discontinue KANJINTI™ in patients experiencing pulmonary toxicity
Exacerbation of Chemotherapy‑Induced Neutropenia
In randomized, controlled clinical trials, the per‑patient incidences of NCI‑CTC Grade 3‑4 neutropenia and of febrile neutropenia were higher in patients receiving trastuzumab in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic death was similar among patients who received trastuzumab and those who did not
Most Common Adverse Reactions
The most common adverse reactions associated with trastuzumab products in breast cancer were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia
The most common adverse reactions associated with trastuzumab products in metastatic gastric cancer were neutropenia, diarrhea, fatigue, anemia, stomatitis, weight loss, upper respiratory tract infections, fever, thrombocytopenia, mucosal inflammation, nasopharyngitis, and dysgeusia
You may report side effects to the FDA at (800) FDA‑1088 or www.fda.gov/medwatch.
You may also report side effects to Amgen at 1‑800‑772‑6436.
INDICATIONS
Adjuvant Breast Cancer
KANJINTI™ is indicated for adjuvant treatment of HER2‑overexpressing node‑positive or node‑negative (ER/PR‑negative or with one high‑risk feature*) breast cancer:
As part of a treatment regimen containing doxorubicin, cyclophosphamide and either paclitaxel or docetaxel
As part of treatment with docetaxel and carboplatin
As a single agent following multi‑modality anthracycline‑based therapy
Select patients for therapy based on an FDA‑approved companion diagnostic for trastuzumab product.
 
 
* High‑risk is defined as ER/PR positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.
 
 
Metastatic Breast Cancer
KANJINTI™ is indicated:
In combination with paclitaxel for the first line treatment of HER2‑overexpressing metastatic breast cancer
As a single agent for treatment of HER2‑overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease
Select patients for therapy based on an FDA‑approved companion diagnostic for trastuzumab product.
Metastatic Gastric Cancer
KANJINTI™ is indicated, in combination with cisplatin and capecitabine or 5‑fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease. Select patients for therapy based on an FDA‑approved companion diagnostic for trastuzumab product.
Please see full Prescribing Information, including Boxed WARNINGS.
 
 
KANJINTI™ is a trademark of Amgen Inc.
Reference: 1. KANJINTI™ (trastuzumab‑anns) Prescribing Information, Amgen.
 
AMGEN
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320‑1799
© 2019 Amgen Inc. All rights reserved. USA‑980‑80089 10/19
Privacy Policy | Terms of Use | Amgen Med Info | Unsubscribe | Amgen Unsubscribe
AMGEN BIOSIMILARS
                                                           
click
This email was sent to amy.gonsuron@amerisourcebergen.com because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.
AmerisourceBergen - 1300 Morris Dr Chesterbrook PA, 19087
© 2019 ION Solutions. All Rights Reserved.